Expertise in
1
conditions

Chunmeng Wang

No. 28 Fuxing Road, 
Beijing, CN 
Expertise in
1
conditions
No. 28 Fuxing Road, 
Beijing, CN 

Overview

Chunmeng Wang practices practicing medicine in Beijing, China.

Wang is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Hodgkin Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Acute Lymphoblastic Leukemia (ALL).

They are actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 28 Fuxing Road, Beijing, 100853, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients
Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Biological
Study Drugs: Decitabine, CD19/CD20-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Enrollment Status: Unknown
Publish Date: April 01, 2019
Intervention Type: Drug
Study Drugs: SHR-1210 Anti-PD-1 Antibody, Decitabine
Study Phase: Phase 2
View 1 Less Clinical Trial

28 Total Publications

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.
Journal: Science advances
Published: May 08, 2026

Frequently Asked Questions about Chunmeng Wang

Is Chunmeng Wang a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Chunmeng Wang is classified as an Advanced expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chunmeng Wang participate in research or clinical trials?

Yes. Chunmeng Wang has published 28 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Chunmeng Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile